We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Pfizer, AT&T, Intuit, Automatic Data Processing and Booking Holdings
Read MoreHide Full Article
For Immediate Release
Chicago, IL – August 30, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer Inc. (PFE - Free Report) , AT&T Inc. (T - Free Report) , Intuit Inc. (INTU - Free Report) , Automatic Data Processing, Inc. (ADP - Free Report) and Booking Holdings Inc. (BKNG - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Analyst Reports for Pfizer, AT&T and Intuit
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer, AT&T, and Intuit. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Pfizer have outperformed the Zacks Large-Cap Pharmaceuticals industry over the past year (+36.6% vs. +23.3%). The Zacks analyst believes that its efforts to drive growth through acquisitions, licensing deals and collaborative agreements bode well.
The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan not only diversify its portfolio of innovative drugs and vaccines but are also likely to boost revenue growth. Its COVID-19 vaccine candidate is now approved for emergency use in several countries and has become a key contributor to the top line. Currency headwinds and pricing pressure are key top-line headwinds though.
AT&T shares have gained +0.1% over the last six months against the Zacks Wireless National industry's gain of +3.2%, but things seem to be improving lately for the company. The Zacks analyst believes that it is well poised to benefit from a solid subscriber growth on the back of a resilient business model and robust cash flow position.
The company aims to spin off its media assets and merge them with the complementary assets of Discovery in order to focus on core operations, reduction of debt burden and monetizing assets. AT&T, however, is witnessing a steady decline in linear TV subscribers as well as legacy services. Its efforts to woo customers with discounts and freebies take a toll on its margins.
Shares of Intuit have gained +47.9% in the year to date period against the Zacks Computer Software industry's gain of +30.8%. The Zacks analyst believes that Intuit has been benefiting from a strong momentum in online ecosystem revenues as well as solid professional tax revenues.
The TurboTax Live offering has also been driving growth in the Consumer tax business. Its strategy of shifting its business to cloud-based subscription model is likely to generate stable revenues in the long term. High costs and expenses due to increased investments in marketing and engineering teams are expected to continue weighing on bottom-line results at least in the near term.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Pfizer, AT&T, Intuit, Automatic Data Processing and Booking Holdings
For Immediate Release
Chicago, IL – August 30, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer Inc. (PFE - Free Report) , AT&T Inc. (T - Free Report) , Intuit Inc. (INTU - Free Report) , Automatic Data Processing, Inc. (ADP - Free Report) and Booking Holdings Inc. (BKNG - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Analyst Reports for Pfizer, AT&T and Intuit
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer, AT&T, and Intuit. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Pfizer have outperformed the Zacks Large-Cap Pharmaceuticals industry over the past year (+36.6% vs. +23.3%). The Zacks analyst believes that its efforts to drive growth through acquisitions, licensing deals and collaborative agreements bode well.
The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan not only diversify its portfolio of innovative drugs and vaccines but are also likely to boost revenue growth. Its COVID-19 vaccine candidate is now approved for emergency use in several countries and has become a key contributor to the top line. Currency headwinds and pricing pressure are key top-line headwinds though.
(You can read the full research report on Pfizer here >>>)
AT&T shares have gained +0.1% over the last six months against the Zacks Wireless National industry's gain of +3.2%, but things seem to be improving lately for the company. The Zacks analyst believes that it is well poised to benefit from a solid subscriber growth on the back of a resilient business model and robust cash flow position.
The company aims to spin off its media assets and merge them with the complementary assets of Discovery in order to focus on core operations, reduction of debt burden and monetizing assets. AT&T, however, is witnessing a steady decline in linear TV subscribers as well as legacy services. Its efforts to woo customers with discounts and freebies take a toll on its margins.
(You can read the full research report on AT&T here >>>)
Shares of Intuit have gained +47.9% in the year to date period against the Zacks Computer Software industry's gain of +30.8%. The Zacks analyst believes that Intuit has been benefiting from a strong momentum in online ecosystem revenues as well as solid professional tax revenues.
The TurboTax Live offering has also been driving growth in the Consumer tax business. Its strategy of shifting its business to cloud-based subscription model is likely to generate stable revenues in the long term. High costs and expenses due to increased investments in marketing and engineering teams are expected to continue weighing on bottom-line results at least in the near term.
(You can read the full research report on Intuit here >>>)
Other noteworthy reports we are featuring today include Automatic Data Processing and Booking Holdings.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.